Personalis, Inc. operates primarily in the precision oncology market, offering genomic sequencing and analytics solutions across the United States and internationally. The company's core business serves two main segments: biopharmaceutical customers utilizing its services for clinical trials and biomarker discovery, and clinical diagnostics for patient monitoring. Key products include the ImmunoID NeXT platform for comprehensive tumor profiling, and NeXT Personal, an ultrasensitive liquid biopsy test designed to detect minimal residual disease (MRD) and cancer recurrence. By combining whole exome (DNA) and whole transcriptome (RNA) sequencing with proprietary algorithms, Personalis enables researchers to track tumor evolution and immune evasion mechanisms. The company operates a CLIA-certified and CAP-accredited laboratory in California, processing tens of thousands of clinical and research samples annually. Its competitive position is supported by its deep sequencing capabilities and strategic partnerships with major pharmaceutical companies and research institutions.
